Differential regulation of muscarinic M1 receptors by orthosteric and allosteric ligands

BMC Pharmacology

Volumn 9, Issue , 2009, Pages

  Davis, Christopher N ^a   Bradley, Stefania R ^a   Schiffer, Hans H ^a   Friberg, Mikael ^a   Koch, Kristian ^a,b   Tolf, Bo Ragnar ^a   Bonhaus, Douglas W ^a   Lameh, Jelveh ^a,c  

^a ACADIA PHARMACEUTICALS INC   (United States)

^b EUROPEAN PATENT OFFICE   (Germany)

^c Genoptix Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AC 260584; AC 42; BETA ARRESTIN 1; CARBACHOL; CLATHRIN; MUSCARINIC M1 RECEPTOR; NORCLOZAPINE; OXOTREMORINE M; PILOCARPINE; PROTEIN INHIBITOR; SUCROSE; UNCLASSIFIED DRUG; XANOMELINE; LIGAND; MUSCARINIC AGENT;

ARTICLE; CELL SURFACE; COATED VESICLE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DOWN REGULATION; DRUG ACTIVITY; DRUG EFFICACY; ENDOCYTOSIS; ENZYME ACTIVATION; ENZYME REGULATION; GENE TRANSLOCATION; HUMAN; HUMAN CELL; HYDROLYSIS; INTERNALIZATION; LIGAND BINDING; PROTEIN INTERACTION; RECEPTOR BINDING; SIGNAL TRANSDUCTION; ALLOSTERISM; ANIMAL; CELL LINE; CHEMISTRY; CHO CELL; COMPARATIVE STUDY; CRICETULUS; DRUG EFFECT; DRUG POTENTIATION; HAMSTER; METABOLISM; PHYSIOLOGY; PROTEIN BINDING;

ALLOSTERIC REGULATION; ANIMALS; CELL LINE; CHO CELLS; CRICETINAE; CRICETULUS; HUMANS; LIGANDS; MUSCARINIC AGONISTS; PROTEIN BINDING; RECEPTOR, MUSCARINIC M1;

EID: 73149088166     PISSN: None     EISSN: 14712210     Source Type: Journal    
DOI: 10.1186/1471-2210-9-14     Document Type: Article

References (38)

1. Ladner CJ, Lee JM. Pharmacological drug treatment of Alzheimer disease: the cholinergic hypothesis revisited. J Neuropathol Exp Neurol 1998, 57(8):719-731. 10.1097/00005072-199808000-00001, 9720487.
2. McKinney M, Coyle JT. The potential for muscarinic receptor subtype-specific pharmacotherapy for Alzheimer's disease. Mayo Clin Proc 1991, 66(12):1225-1237.
3. Bymaster FP, Carter PA, Peters SC, Zhang W, Ward JS, Mitch CH, Calligaro DO, Whitesitt CA, DeLapp N, Shannon HE. Xanomeline compared to other muscarinic agents on stimulation of phosphoinositide hydrolysis in vivo and other cholinomimetic effects. Brain Res 1998, 795(1-2):179-190. 10.1016/S0006-8993(98)00267-4, 9622623.
4. Spalding TA, Ma JN, Ott TR, Friberg M, Bajpai A, Bradley SR, Davis RE, Brann MR, Burstein ES. Structural requirements of transmembrane domain 3 for activation by the M1 muscarinic receptor agonists AC-42, AC-260584, clozapine, and N-desmethylclozapine: evidence for three distinct modes of receptor activation. Mol Pharmacol 2006, 70(6):1974-1983. 10.1124/mol.106.024901, 16959945.
5. Spalding TA, Trotter C, Skjaerbaek N, Messier TL, Currier EA, Burstein ES, Li D, Hacksell U, Brann MR. Discovery of an ectopic activation site on the M(1) muscarinic receptor. Mol Pharmacol 2002, 61(6):1297-1302. 10.1124/mol.61.6.1297, 12021390.
6. Ward JS, Merritt L, Calligaro DO, Bymaster FP, Shannon HE, Mitch CH, Whitesitt C, Brunsting D, Sheardown MJ, Olesen PH. 1,2,5-Thiadiazole analogues of aceclidine as potent m1 muscarinic agonists. J Med Chem 1998, 41(3):379-392. 10.1021/jm970125n, 9464368.
7. Ward JS, Merritt L, Calligaro DO, Bymaster FP, Shannon HE, Sawyer BD, Mitch CH, Deeter JB, Peters SC, Sheardown MJ. Functionally selective M1 muscarinic agonists. 3. Side chains and azacycles contributing to functional muscarinic selectivity among pyrazinylazacycles. J Med Chem 1995, 38(18):3469-3481. 10.1021/jm00018a007, 7658434.
8. Wood MD, Murkitt KL, Ho M, Watson JM, Brown F, Hunter AJ, Middlemiss DN. Functional comparison of muscarinic partial agonists at muscarinic receptor subtypes hM1, hM2, hM3, hM4 and hM5 using microphysiometry. Br J Pharmacol 1999, 126(7):1620-1624. 10.1038/sj.bjp.0702463, 1565933, 10323594.
9. Sur C, Mallorga PJ, Wittmann M, Jacobson MA, Pascarella D, Williams JB, Brandish PE, Pettibone DJ, Scolnick EM, Conn PJ. N-desmethylclozapine, an allosteric agonist at muscarinic 1 receptor, potentiates N-methyl-D-aspartate receptor activity. Proc Natl Acad Sci USA 2003, 100(23):13674-13679. 10.1073/pnas.1835612100, 263872, 14595031.
10. Jakubik J, El-Fakahany EE, Dolezal V. Differences in kinetics of xanomeline binding and selectivity of activation of G proteins at M(1) and M(2) muscarinic acetylcholine receptors. Mol Pharmacol 2006, 70(2):656-666. 10.1124/mol.106.023762, 16675658.
11. Jakubik J, Tucek S, El-Fakahany EE. Allosteric modulation by persistent binding of xanomeline of the interaction of competitive ligands with the M1 muscarinic acetylcholine receptor. J Pharmacol Exp Ther 2002, 301(3):1033-1041. 10.1124/jpet.301.3.1033, 12023535.
12. Langmead CJ, Christopoulos A. Allosteric agonists of 7TM receptors: expanding the pharmacological toolbox. Trends Pharmacol Sci 2006, 27(9):475-481. 10.1016/j.tips.2006.07.009, 16889837.
13. De Lorme KC, Grant MK, Noetzel MJ, Polson SB, El-Fakahany EE. Long-term changes in the muscarinic M1 receptor induced by instantaneous formation of wash-resistant xanomeline-receptor complex. J Pharmacol Exp Ther 2007, 323(3):868-876. 10.1124/jpet.107.129940, 17855477.
14. Thomas RL, Mistry R, Langmead CJ, Wood MD, Challiss RA. G protein coupling and signaling pathway activation by m1 muscarinic acetylcholine receptor orthosteric and allosteric agonists. J Pharmacol Exp Ther 2008, 327(2):365-374. 10.1124/jpet.108.141788, 18664591.
15. Langmead CJ, Fry VA, Forbes IT, Branch CL, Christopoulos A, Wood MD, Herdon HJ. Probing the molecular mechanism of interaction between 4-n-butyl-1-[4-(2-methylphenyl)-4-oxo-1-butyl]-piperidine (AC-42) and the muscarinic M(1) receptor: direct pharmacological evidence that AC-42 is an allosteric agonist. Mol Pharmacol 2006, 69(1):236-246.
16. De Lorme KC, Sikorski KL, Grant MK, El-Fakahany EE. Long-term wash-resistant effects of brief interaction of xanomeline at the M1 muscarinic receptor. Neurosci Lett 2006, 410(1):11-14. 10.1016/j.neulet.2006.09.062, 1850384, 17052840.
17. Tolbert LM, Lameh J. Human muscarinic cholinergic receptor Hm1 internalizes via clathrin-coated vesicles. J Biol Chem 1996, 271(29):17335-17342. 10.1074/jbc.271.29.17335, 8663385.
18. Gaborik Z, Szaszak M, Szidonya L, Balla B, Paku S, Catt KJ, Clark AJ, Hunyady L. Beta-arrestin- and dynamin-dependent endocytosis of the AT1 angiotensin receptor. Mol Pharmacol 2001, 59(2):239-247.
19. McAbee DD, Oka JA, Weigel PH. Loss of surface galactosyl receptor activity on isolated rat hepatocytes induced by monensin or chloroquine requires receptor internalization via a clathrin coated pit pathway. Biochem Biophys Res Commun 1989, 161(1):261-266. 10.1016/0006-291X(89)91589-1, 2567166.
20. Olli-Lahdesmaki T, Scheinin M, Pohjanoksa K, Kallio J. Agonist-dependent trafficking of alpha2-adrenoceptor subtypes: dependence on receptor subtype and employed agonist. Eur J Cell Biol 2003, 82(5):231-239. 10.1078/0171-9335-00311, 12800978.
21. Shockley MS, Burford NT, Sadée W, Lameh J. Residues Specifically Involved in Down-regulation but not Internalization of the Muscarinic Acetylcholine Receptor. J Neurochem 1997, 68:601-609.
22. Claing A, Laporte SA, Caron MG, Lefkowitz RJ. Endocytosis of G protein-coupled receptors: roles of G protein-coupled receptor kinases and beta-arrestin proteins. Prog Neurobiol 2002, 66(2):61-79. 10.1016/S0301-0082(01)00023-5, 11900882.
23. Nelson CD, Perry SJ, Regier DS, Prescott SM, Topham MK, Lefkowitz RJ. Targeting of diacylglycerol degradation to M1 muscarinic receptors by beta-arrestins. Science 2007, 315(5812):663-666. 10.1126/science.1134562, 17272726.
24. van Koppen CJ. Multiple pathways for the dynamin-regulated internalization of muscarinic acetylcholine receptors. Biochem Soc Trans 2001, 29(Pt 4):505-508. 10.1042/BST0290505, 11498018.
25. van Koppen CJ, Kaiser B. Regulation of muscarinic acetylcholine receptor signaling. Pharmacol Ther 2003, 98(2):197-220. 10.1016/S0163-7258(03)00032-9, 12725869.
26. Vogler O, Nolte B, Voss M, Schmidt M, Jakobs KH, van Koppen CJ. Regulation of muscarinic acetylcholine receptor sequestration and function by beta-arrestin. J Biol Chem 1999, 274(18):12333-12338. 10.1074/jbc.274.18.12333, 10212203.
27. von Zastrow M. Mechanisms regulating membrane trafficking of G protein-coupled receptors in the endocytic pathway. Life Sci 2003, 74(2-3):217-224. 10.1016/j.lfs.2003.09.008, 14607249.
28. Richards MH, van Giersbergen PL. Human muscarinic receptors expressed in A9L and CHO cells: activation by full and partial agonists. Br J Pharmacol 1995, 114(6):1241-1249. 1510344, 7620715.
29. Figueroa KW, Griffin MT, Ehlert FJ. Selectivity of agonists for the active state of M1 to M4 muscarinic receptor subtypes. J Pharmacol Exp Ther 2009, 328(1):331-342. 10.1124/jpet.108.145219, 18824613.
30. Luttrell LM, Ferguson SS, Daaka Y, Miller WE, Maudsley S, Della Rocca GJ, Lin F, Kawakatsu H, Owada K, Luttrell DK. Beta-arrestin-dependent formation of beta2 adrenergic receptor-Src protein kinase complexes. Science 1999, 283(5402):655-661. 10.1126/science.283.5402.655, 9924018.
31. Werbonat Y, Kleutges N, Jakobs KH, van Koppen CJ. Essential role of dynamin in internalization of M2 muscarinic acetylcholine and angiotensin AT1A receptors. J Biol Chem 2000, 275(29):21969-21974. 10.1074/jbc.M001736200, 10801820.
32. Bonner TI, Buckley NJ, Young AC, Brann MR. Identification of a family of muscarinic acetylcholine receptor genes. Science 1987, 237(4814):527-532. 10.1126/science.3037705, 3037705.
33. Arden J, Lameh J. Agonist-induced internalization of human ml muscarinic receptor mutants: immunofluorescence confocal microscopy. Proc West Pharmacol Soc 1996, 39:51-54.
34. Lameh J, Philip M, Sharma YK, Moro O, Ramachandran J, Sadée W. Hm1 Muscarinic Cholinergic Receptor Internalization Requires a Domain in the Third Cytoplasmic Loop. J Biol Chem 1992, 267:13406-13412.
35. Maeda S, Lameh J, Mallet WG, Philip M, Ramachandran J, Sadée W. Internalization of the Hm1 muscarinic cholinergic receptor involves the third cytoplasmic loop. FEBS Lett 1990, 269(2):386-388. 10.1016/0014-5793(90)81199-X, 2401364.
36. Yang J, Williams JA, Yule DI, Logsdon CD. Mutation of carboxyl-terminal threonine residues in human m3 muscarinic acetylcholine receptor modulates the extent of sequestration and desensitization. Mol Pharmacol 1995, 48(3):477-485.
37. Schiffer HH, Reding EC, Fuhs SR, Lu Q, Piu F, Wong S, Littler PL, Weiner DM, Keefe W, Tan PK. Pharmacology and signaling properties of epidermal growth factor receptor isoforms studied by bioluminescence resonance energy transfer. Mol Pharmacol 2007, 71(2):508-518. 10.1124/mol.106.027656, 16968809.
38. Högger P, Shockley MS, Lameh J, Sadée W. Activating and inactivating mutations in N- and C-terminal i3 loop junctions of muscarinic acetylcholine Hm1 receptors. J Biol Chem 1995, 270(13):7405-7410. 10.1074/jbc.270.13.7405, 7706286.